[1]張 婷.噬血細胞綜合征治療進展[J].醫學信息,2019,(22):46-48.[doi:10.3969/j.issn.1006-1959.2019.22.015]
 ZHANG Ting.Progress in the Treatment of Hemophagocytic Syndrome[J].Medical Information,2019,(22):46-48.[doi:10.3969/j.issn.1006-1959.2019.22.015]
點擊復制

噬血細胞綜合征治療進展()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
46-48
欄目:
綜述
出版日期:
2019-11-15

文章信息/Info

Title:
Progress in the Treatment of Hemophagocytic Syndrome
文章編號:
1006-1959(2019)22-0046-03
作者:
張 婷
(天津市兒童醫院血液科,天津 300000)
Author(s):
ZHANG Ting
(Department of Hematology,Tianjin Children's Hospital,Tianjin 300000,China)
關鍵詞:
噬血細胞綜合征免疫炎癥反應
Keywords:
Hemophagocytic syndromeImmunityInflammatory response
分類號:
R725.5
DOI:
10.3969/j.issn.1006-1959.2019.22.015
文獻標志碼:
A
摘要:
噬血細胞綜合征(HPS)又稱為噬血細胞性淋巴組織細胞增生癥,是一種病理性免疫激活引起過度炎癥反應的臨床綜合征,臨床分為繼發性和原發性。由于病因多,發病機制復雜,臨床表現多樣化,診斷難度大,漏診、誤診的可能性大。本文就HPS的病因、發病機制、診斷及治療等方面的研究進展進行綜述,以期為臨床診治HPS提供一定的理論依據。
Abstract:
Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis, is a clinical syndrome in which pathological immune activation causes excessive inflammatory response, clinically divided into secondary and primary. Due to many causes, the pathogenesis is complicated, the clinical manifestations are diversified, the diagnosis is difficult, and the possibility of missed diagnosis and misdiagnosis is high. This article reviews the research progress in the etiology, pathogenesis, diagnosis and treatment of HPS, in order to provide a theoretical basis for clinical diagnosis and treatment of HPS.

參考文獻/References:

[1]李碩,王晶石,王旖旎,等.147例噬血細胞綜合征病因及預后分析[J].臨床血液學雜志,2014,27(7):559-563. [2]李佩章,王英,龐乃奇,等.淋巴瘤相關噬血細胞綜合征的臨床特點、診斷及治療(附20例分析)[J].山東醫藥,2017,57(31):47-49. [3]Broglie L,Pommert L,Rao S,et al.Ruxolitinib for treatment of refractoryhemophagocytic lymphohistiocytosis[J].Blood Adv,2017,1(19):1533-1536. [4]徐曉軍,湯永民,宋華,等.Th1/Th2細胞因子譜在兒童噬血細胞綜合征早期快速診斷中的意義[J].中華兒科雜志,2014,49(9):685-689. [5]付麗,魏娜,王晶石,等.異基因造血干細胞移植治療原發性噬血細胞綜合征合并中樞神經系統病變病例報告[J].內科急危重癥雜志,2016,22(3):171-175. [6]何秋連,曹紅,馬春蓉,等.EB病毒感染相關噬血細胞綜合征的診治分析[J].西部醫學,2017,29(5):689-693. [7]陳莉,游泳,張文靜,等.蘆可替尼在噬血細胞綜合征中的應用[J].臨床血液學雜志,2018,31(3):219-221. [8]陳兵,歐陽建,周榮富,等.40例噬血細胞綜合征的臨床特點及預后分析[J].中國現代醫學雜志,2014,20(4):592-594,598. [9]Brito-Zeron P,Retamozo S,AkssbiM,etal.Annular erythema in prmaary Sjogrens syndrome;description of 43non-Asian cases[J].Lupus,2014,23(2):166-175. [10]王旖旎,黃文秋,魏娜,等.DEP方案挽救治療成人難治性噬血細胞綜合征的臨床研究[J].中華血液學雜志,2014,35(10):901-904. [11]孫瑞娟,肖娟,張建平,等.異基因造血干細胞移植治療噬血細胞綜合征[J].中華兒科雜志,2014,52(2):94-98. [12]Schram AM ,Berliner N.How I treat hemophagocytic lymphohistiocytosis inthe adult patient[J]. Blood,2015,125(19):2908-2914. [13]王昭.噬血細胞性淋巴組織細胞增生癥的診斷[J].內科理論與實踐,2014,8(3):157-162. [14]唐雪梅,趙曉東.噬血細胞綜合征遺傳特點與免疫發病機制[J].中國實用兒科雜志,2015(10):744-747. [15]Janka GE.Familial and Acquired Hemophagocytic Lymphohistiocytosis[J].Annual Review of Medicine,2014(63):233-246. [16]Imashuku S.Hemophagocytic lymphohistiocytosis: Recentprogress in the pathogenesis, diagnosis and treatment[J].World Journal ofHematology,2014,3(3):71-84. [17]賈紅英,孟昭生,劉紅.噬血細胞綜合征實驗室診斷和臨床分析[J].醫學檢驗與臨床,2015,23(4):17-18,24. [18]王旖旎,王昭,吳林.多中心72例噬血細胞綜合征診療分析[J].中華血液學雜志,2014,30(12):793-798. [19]Brito-Zerón P,Bosch X,Pérez-de-Lis M,et al.Infection is the majortrigger of hemophagocytic syndrome in adult patients treated withbiological therapies[J].Semin Arthritis Rheum,2016,45(4):391-399. [20]章琴,高清平,康玉敬.成人嗜血細胞綜合征的臨床分析[J].內科急危重癥雜志,2014,9(2):102-103. [21]王宇,李碩,閆麗娟,等.血清HO-1水平在獲得性噬血細胞綜合征中的臨床意義探討[J].臨床和實驗醫學雜志,2015,12(20):1609-1611. [22]劉燕鷹,周妹含,張莉,等.噬血細胞綜合征77例臨床分析[J].中華醫學雜志,2015,95(9):681-684. [23]王玲,尹春燕,肖延風,等.噬血細胞綜合征(HPS)鑒別診斷和實驗室結果分析[J].現代檢驗醫學雜志,2016,31(4):107-109. [24]劉冰,呂曉嫻,張玉姬.噬血細胞綜合征臨床分析[J].檢驗醫學,2014,24(7):528-529. [25]高卓,王昭.重視實驗室檢測對噬血細胞綜合征的診斷價值[J].中華檢驗醫學雜志,20155,38(11):727-729.

相似文獻/References:

[1]張林.圍術期輸血對胃癌根治術患者預后及免疫的影響[J].醫學信息,2018,(01):94.[doi:10.3969/j.issn.1006-1959.2018.01.033]
 ZHANG Lin.Effect of Perioperative Blood Transfusion on Prognosis and Immunity of Patients with Radical Gastrectomy[J].Medical Information,2018,(22):94.[doi:10.3969/j.issn.1006-1959.2018.01.033]
[2]白 雪,朱海波,鄧 琦,等.PD-L1在急性髓系白血病中的表達及臨床意義[J].醫學信息,2019,(06):79.[doi:10.3969/j.issn.1006-1959.2019.06.025]
 BAI Xue,ZHU Hai-bo,DENG Qi,et al.Expression and Clinical Significance of PD-L1 in Acute Myeloid Leukemia[J].Medical Information,2019,(22):79.[doi:10.3969/j.issn.1006-1959.2019.06.025]
[3]張華雄,李 吉.玫瑰痤瘡先天免疫及周圍神經相關致病機理研究進展[J].醫學信息,2019,(08):53.[doi:10.3969/j.issn.1006-1959.2019.08.017]
 ZHANG Hua-xiong,LI Ji.Research Progress on Innate Immunity and Peripheral Nerve-related Pathogenesis of Rosacea[J].Medical Information,2019,(22):53.[doi:10.3969/j.issn.1006-1959.2019.08.017]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩